Glaukos - Public Comps and Valuation Multiples

Glaukos Overview

About Glaukos

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Founded

1998

HQ

Employees

995

Website

glaukos.com

Sectors

Medical Devices
DeepTech
HealthTech

Financials

LTM Revenue $411M

LTM EBITDA -$35.3M

EV

$5.0B

Valuation Multiples

Multiples.vc

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Glaukos Financials

Glaukos has a last 12-month revenue of $411M and a last 12-month EBITDA of -$35.3M.

In the most recent fiscal year, Glaukos achieved revenue of $383M and an EBITDA of -$95.6M.

Glaukos expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Glaukos valuation multiples based on analyst estimates

Glaukos P&L

	FY 2023	FY 2024	FY 2025	LTM	NTM
Revenue	$315M	$383M	XXX	XXX	XXX
Gross Profit	$214M	$239M	XXX	XXX	XXX
Gross Margin	68%	62%	XXX	XXX	XXX
EBITDA	-$82.1M	-$95.6M	XXX	XXX	XXX
EBITDA Margin	-26%	-25%	XXX	XXX	XXX
Net Profit	-$99.2M	-$135M	XXX	XXX	XXX
Net Margin	-32%	-35%	XXX	XXX	XXX
Net Debt	$162M	$189M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

Glaukos Stock Performance

As of April 15, 2025, Glaukos's stock price is $93.

Glaukos has current market cap of $5.3B, and EV of $5.0B.

See Glaukos trading valuation data

Glaukos Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$5.0B	$5.3B	XXX	XXX	XXX	XXX	$-1.61

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Glaukos Valuation Multiples

As of April 15, 2025, Glaukos has market cap of $5.3B and EV of $5.0B.

Glaukos's trades at 12.3x LTM EV/Revenue multiple, and -142.9x LTM EBITDA.

Analysts estimate Glaukos's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See valuation multiples for Glaukos and 10K+ public comps

Glaukos Financial Valuation Multiples

	FY 2024	FY 2025E	FY 2026E	FY 2027E
EV	$5.0B	XXX	XXX	XXX
EV/Revenue	13.1x	XXX	XXX	XXX
EV/EBITDA	-52.7x	XXX	XXX	XXX
P/E	-35.9x	XXX	XXX	XXX
P/E/Growth	n/a	XXX	XXX	XXX
EV/FCF	-74.5x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Glaukos Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Glaukos Valuation Multiples

Glaukos's NTM/LTM revenue growth is 26%

Glaukos's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.4M for the same period.

Over next 12 months, Glaukos's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .

Analysts estimate Glaukos's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See operational valuation multiples for Glaukos and other 10K+ public comps

Glaukos Operational Valuation Multiples

	FY 2024	NTM	FY 2025E	FY 2026E	FY 2027E
Revenue Growth	22%	XXX	XXX	XXX	XXX
EBITDA Margin	-25%	XXX	XXX	XXX	XXX
EBITDA Growth	16%	XXX	XXX	XXX	XXX
Rule of 40 (SaaS-only)	1%	XXX	XXX	XXX	XXX
Revenue per Employee	$0.4M	XXX	XXX	XXX	XXX
Opex per Employee	$0.4M	XXX	XXX	XXX	XXX
S&M Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
G&A Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
R&D Expenses to Revenue	36%	XXX	XXX	XXX	XXX
Opex to Revenue	104%	XXX	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry